We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Institut Pasteur Korea Selects ActivityBase™ as its Screening Solution of Choice


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Institut Pasteur Korea Selects ActivityBase™ as its Screening Solution of Choice"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

IDBS has announced that Institut Pasteur - Korea has implemented the ActivityBase data management software suite to increase efficiency and throughput in its screening operations.

Institut Pasteur Korea (IP-K), a Research Center located in Seoul, South Korea, has purchased ActivityBase to handle their biology and chemistry data for High Throughput and High Content Screening (HTS/HCS).

IP-K is implementing HCS assays and platforms for Drug Discovery using cell-based models of disease and automated confocal microscopy.

IP-K will use ActivityBase suite to consolidate chemistry information and screening results, including those from microscopy-based screens, in a single Oracle database.

Institut Pasteur Korea decided to purchase ActivityBase as its researchers felt more secure with a system with a proven track record in Drug Discovery.

Dr. Thierry Christophe, the Head of the Screening and Pharmacology lab, has used ActivityBase in previous positions at other companies.

He said, "I am happy to be working with ActivityBase again, as it is a robust and flexible system that I know can deliver the results we need."

"We plan to develop specific data analysis templates for High Content Screens allowing the manipulation of multiplexing data from one single screen."

Neil Kipling, IDBS’ Chairman and CEO, commented, "The increase in HCS and HTS planned by IP-K’s screening group demanded a data management system that could scale up to their requirements, both now and in the future, as well as map closely to their workflow."

"We are delighted to be supporting a centre of excellence in biomedical research and technology development, allowing new drugs to be identified faster and more reliably."

Advertisement